Ipsen has announced results from its ENGAGE study for the combination of Dysport (abobotulinumtoxinA) alongside Guided Self-rehabilitation contracts (GSC) which both improved patients voluntary movement as measured by a composite active range of motion outcome.
ENGAGE si the first study to investigate treatment with Dysport in patients with spastic hemiparesis in both the upper and lower limbs in combination with GSC.
